Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer

被引:11
|
作者
Yun, Chen [2 ]
Gang, Li [1 ]
Gu Rongmin [1 ]
Xu, Wen [1 ]
Ming Xuezhi [1 ]
Chen Huanqiu [1 ]
机构
[1] Nanjing Med Univ, Dept Gen Surg, Gastr Tumor Ctr, Jiangsu Canc Hosp,Affiliated Canc Hosp, Nanjing 210009, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210009, Jiangsu, Peoples R China
基金
中国博士后科学基金;
关键词
Her2; Her3; Met; gastric cancer; BREAST-CANCER; TARGETED THERAPIES; RECEPTOR; RESISTANCE; MECHANISMS;
D O I
10.1002/mc.22241
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Various receptor tyrosine kinase (RTK) pathways were verified in many cancers including gastric cancer (GC), We sought to investigate the expression of RTKs including Her2, Her3, and Met and their transduction patterns in human GC. Over-expression of Her2, Her3, and c-Met in human GC was verified by immunohistochemistry leading to constitutive activation of RTK signaling pathways. Combined RTKs expression was valuable indicators for poor prognosis of GC patients. Using ErbB2 specific inhibitor Lapatinib and c-Met specific inhibitor PHA-665752, we further demonstrated that this constitutive activation of RTK signaling is necessary for the survival of GC cells. However, various RTK pattern: Her3/Her2 and Met/Her3 were verified in the transduction growth stimulus from outside via both AKT and MAPK signaling. Moreover, the essential roles of Her3 in both two heterodimers were obtained which showed significantly attenuated growth effect due to Her3 knockdown both in vitro and in vivo. In conclusion, various molecular transduction patterns: Her2/Her3 and Met/Her3 were verified in human GC, and Her3 could serve as a potential target in GC treatment. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1700 / 1709
页数:10
相关论文
共 50 条
  • [31] HER3 as a Therapeutic Target in Cancer
    Karachaliou, Niki
    Lazzari, Chiara
    Verlicchi, Alberto
    Sosa, Aaron E.
    Rosell, Rafael
    [J]. BIODRUGS, 2017, 31 (01) : 63 - 73
  • [32] Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer
    Krähn, G
    Leiter, U
    Kaskel, P
    Udart, M
    Utikal, J
    Bezold, G
    Peter, RU
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (02) : 251 - 259
  • [33] EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer
    Fichter, Christiane Daniela
    Timme, Sylvia
    Braun, Julia Alexandra
    Gudernatsch, Verena
    Schoepflin, Anja
    Bogatyreva, Lioudmilla
    Geddert, Helene
    Faller, Gerhard
    Klimstra, David
    Tang, Laura
    Hauschke, Dieter
    Werner, Martin
    Lassmann, Silke
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (07) : 1517 - 1530
  • [34] Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway
    Xiaoyu Wu
    Yun Chen
    Gang Li
    Lei Xia
    Rongmin Gu
    Xu Wen
    Xuezhi Ming
    Huanqiu Chen
    [J]. Medical Oncology, 2014, 31
  • [35] Regulation of ERBB3/HER3 signaling in cancer
    Mujoo, Kalpana
    Choi, Byung-Kwon
    Huang, Zhao
    Zhang, Ningyan
    An, Zhiqiang
    [J]. ONCOTARGET, 2014, 5 (21) : 10222 - 10236
  • [36] Critical role and mechanism of WASF3 in HER2/HER3 regulation of breast cancer metastasis
    Teng, Yong
    Pi, Wenhu
    Cowell, John
    [J]. CANCER RESEARCH, 2016, 76
  • [37] Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer
    Alejandro Perez-Fidalgo, Jose
    Tarazona, Noelia
    Navarro, Samuel
    Lopez-Mozos, Fernando
    Marti, Roberto
    Rosello Keranen, Susana
    Roda Perez, Desamparados
    Mongort, Cristina
    Cervantes-Ruiperez, Andres
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Quantification of HER2/HER3 Dimerisation Status in Primary Invasive Breast Cancer
    Barros, F. F. T.
    Abdel-Fatah, T. M. A.
    Rakha, E. A.
    Chan, S.
    Green, A. R.
    Ellis, I. O.
    [J]. JOURNAL OF PATHOLOGY, 2012, 228 : S14 - S14
  • [39] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
  • [40] The involvement of EGFR, HER2 and HER3 in the basal cell carcinomas aggressiveness
    Florescu, Diana Elena
    Stepan, Alex Emilian
    Margaritescu, Claudiu
    Ciurea, Raluca Niculina
    Stepan, Mioara-Desdemona
    Simionescu, Cristiana Eugenia
    [J]. ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2018, 59 (02): : 479 - 484